Form 4: Avalo Therapeutics Insider Trades Under 10b5-1 Plan

Avalo Therapeutics Chief Medical Officer Mittie Doyle executed trades under a pre-arranged Rule 10b5-1 plan, acquiring and disposing of company stock.

Summary

• Mittie Doyle, Chief Medical Officer at Avalo Therapeutics, Inc., engaged in stock transactions on June 30, 2026, under a Rule 10b5-1 trading plan established on November 13, 2025.
• Doyle acquired 2,875 shares of common stock at $12.65 per share and an additional 1,779 shares at $8.04 per share.
• Concurrently, Doyle disposed of 4,654 shares of common stock at a price of $20 per share.
• Following these transactions, Doyle beneficially owns 51,776 shares of common stock directly.
• The filing also details stock options, including 2,875 options with an exercise price of $12.65 and 1,779 options with an exercise price of $8.04, with specific vesting schedules tied to continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral; it reports on routine insider transactions executed under a pre-established plan, providing transparency without strong positive or negative indicators for the company's stock.

Positives

• The use of a Rule 10b5-1 plan indicates pre-planned, transparent trading activity by management, mitigating concerns about insider trading.
• Acquisition of shares at varying price points ($12.65 and $8.04) suggests a potential belief in the stock's value at those levels.
• The disposal of shares at $20 per share indicates a profitable exit for a portion of the holdings.

Negatives

• The disposal of 4,654 shares at $20 per share, while profitable, represents a reduction in the reporting person's direct stock ownership.
• The specific details of the Rule 10b5-1 plan, including the rationale for the amounts and prices, are not fully elaborated in the filing.

Risks

• The vesting schedules for stock options are contingent on continued service, meaning any departure from the company could impact the realization of these options.
• The disposal of shares, even under a 10b5-1 plan, could be interpreted negatively by the market if not accompanied by other positive company news.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding the company's future financial performance. It solely reports on past transactions by an insider.

Management Comments

• The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.
• The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.
• The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.

Industry Context

StockSavvy.ai notes that the use of Rule 10b5-1 plans by executives is a common practice in the biotechnology and pharmaceutical sectors to manage personal stock portfolios while adhering to insider trading regulations. This filing indicates standard compliance procedures are being followed by Avalo Therapeutics' management.

Corporate Governance

Stakeholder Impact

• Shareholders: The filing provides transparency into insider activity, which can influence investor confidence. The disposal of shares, though planned, might be viewed with caution.
• Employees: The vesting schedules for stock options are tied to continued employment, incentivizing retention.
• Management: Demonstrates adherence to regulatory requirements for insider trading.

Next Steps

• Continued adherence to the Rule 10b5-1 trading plan for future transactions.
• Vesting of stock options according to the specified schedules, contingent on continued service.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Rule 10b5-1, Avalo Therapeutics, AVTX, Stock Options, Beneficial Ownership, Stock Transactions, Chief Medical Officer